The somatic hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable
(IGHV) gene is a critical biomarker for assessing the prognosis of patients with chronic …

Background The treatment landscape for chronic lymphocytic leukemia (CLL) continues to
undergo considerable evolution. Optimal selection of initial therapy from multiple effective …

Background Randomized trials of venetoclax plus anti-CD20 antibodies as first-line
treatment in fit patients (ie, those with a low burden of coexisting conditions) with advanced …

Background The combination of ibrutinib and venetoclax has been shown to improve
outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with …

Data on long-term outcomes and biological drivers associated with depth of remission after
BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are …

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine …

The B cell leukemia/lymphoma 2 (BCL-2) inhibitor venetoclax is effective in chronic
lymphocytic leukemia (CLL); however, resistance may develop over time. Other lymphoid …

Background In the GLOW study, fixed-duration ibrutinib–venetoclax showed superior
progression-free survival versus chlorambucil–obinutuzumab in patients with previously …

PURPOSE In GLOW, fixed-duration ibrutinib+ venetoclax showed superior progression-free
survival (PFS) versus chlorambucil+ obinutuzumab in older/comorbid patients with …

The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed
considerably with the introduction of very effective oral targeted therapies (such as Bruton …